Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Nanopatch Vaccine Technology Company Attracts $25M

February 10, 2015 9:34 am | by University of Queensland | News | Comments

Vaccine technology company Vaxxas has moved a step closer to achieving its goal of improving world health, thanks to a capital raising of $25 million. Read more...                           


Reducing Animal Testing One Chip at a Time

February 10, 2015 9:19 am | by Michelle Taylor, Editor-in-Chief, Lab Equipment | Articles | Comments

Speaking to a room of pharmaceutical scientists, Donald Ingber started off his Keynote presentation at SLAS 2015 in Washington D.C. by saying that “the current drug development model is broken.” He pointed to Eroom’s Law (Moore’s law backward) as proof. Read more...


CDK4/6 Inhibitor: Promising Results for Treating Breast Cancer

February 9, 2015 1:06 pm | by Drug Discovery & Development staff | Articles | Comments

The words “exciting,” “breakthrough,” and “standard-of-care-changing” are being used with regard to cyclin-dependent kinase (CDK) 4 and 6 inhibitors and metastatic breast cancer. Read more...                                       


Achillion Shares Soar Following Hepatitis C Drug Update

February 9, 2015 11:57 am | by Associated Press | News | Comments

Shares of Achillion Pharmaceuticals Inc. jumped Monday morning after the drug developer said a small group of patients who took its experimental hepatitis C treatment combination remained free of the liver-destroying virus three months after they stopped taking doses. Read more...


Measles Cases Turn Attention to Bounty of Childhood Vacccines

February 9, 2015 11:46 am | by Lindsey Tanner, AP Medical Writer - Associated Press | News | Comments

Measles is in the news, but it's just one of more than a dozen preventable - and sometimes forgotten - diseases targeted by vaccines for children. Read more...                                  


Supplements Industry Derides NY Attorney General's DNA Tests

February 9, 2015 11:32 am | by Mary Esch, Associated Press | News | Comments

DNA barcoding has exposed some infamous cases of food fraud, like cheap catfish sold as pricey grouper and expensive "sheep's milk" cheese that was really made from cow's milk. But can it tell if a pill touted as an energy-booster contains ginseng or is just a mix of rice powder and pine? Read more...


Meet the New ACS CEO: Tom Connelly

February 6, 2015 4:33 pm | by Michelle Taylor, Editor-in-Chief, Laboratory Equipment | Articles | Comments

Come February 17, Thomas M. Connelly, Jr. will be the new CEO of the American Chemical Society (ACS), taking over for Madeleine Jacobs, who is retiring after 11 years as CEO and a total of 24 years with ACS. Connelly talks about the challenges the chemistry industry faces today. Read more... 


Sick With Measles, Again

February 6, 2015 4:23 pm | by Alvin Powell, Harvard Staff Writer | News | Comments

Last year was the worst for measles in the United States since the country was declared free of the disease in 2000. This year is not off to a promising start. The measles outbreak that began in Disneyland in December has continued to spread, infecting 102 people in 14 states during January, according to the Centers for Disease Control and Prevention (CDC). Read more...


Hackers See Rewarding Targets in Health Care Companies

February 6, 2015 4:17 pm | by Tom Murphy and Brandon Bailey, AP Business Writers - Associated Press | News | Comments

Health care is a treasure trove for criminals looking to steal reams of personal information, as the hacking of a database maintained by the second-largest U.S. health insurer proves. Read more...                                      


Insight Into Nerve Cells Could Lead to Alzheimer's Drugs

February 6, 2015 4:12 pm | by University of Queensland | News | Comments

New insights into how nerves cells in the brain maintain efficient communication with each other may help offset the effects of Alzheimer’s disease. Read more...                                            


A Look at Some Vaccine-Related Legislation in Several States

February 6, 2015 4:07 pm | by Associated Press | News | Comments

Several state legislatures are debating vaccine-related measures as dozens of people have fallen ill from a measles outbreak that started at Disneyland in December and spread beyond the theme park. Here is a look at some of the legislation around the country. Read more...


Evaluating Strategies for HIV Vaccinations

February 6, 2015 4:03 pm | by Anne Trafton, MIT | News | Comments

Through an investigation of a fundamental process that guides the maturation of immune cells, researchers have revealed new insights into possible ways to vaccinate people to generate potent antibodies of the type that are predicted to offer protection against diverse strains of the highly mutable HIV. Read more...


Carribbean Blues: Mosquito Virus is Sickening More Travelers

February 6, 2015 2:22 pm | by Associated Press | News | Comments

Thousands of travelers to the Caribbean and nearby regions are coming home with an unwanted souvenir: a mosquito-borne virus that recently settled there. Read more...                         


Drug Combinations May be Good Approach for Infectious Fungus

February 6, 2015 2:12 pm | by University of Toronto | News | Comments

Researchers at the University of Toronto have discovered that Candida albicans—a leading cause of potentially fatal hospital-acquired infections—rarely develops resistance to combination drug therapy and, when it becomes resistant, it also becomes less dangerous. Read more...


Pfizer Acquisition of Hospira Lays Foundation for Potential Generics Unit Spin-off

February 6, 2015 2:06 pm | by Pfizer | News | Comments

Adam Dion, MS, GlobalData’s Healthcare Industry Analyst, says: “On 5 February 2015, just days after gaining US Food and Drug Administration (FDA) breakthrough approval for Ibrance (palbociclib) in breast cancer, Pfizer entered into an agreement to purchase generic drug maker Hospira for $90 per share in cash, or approximately $17 billion, representing about a 40 percent premium above Hospira’s stock price." Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.